| The effect of myo-inositol supplementation on the prevention of gestational diabetes in overweight pregnant women: a randomized, double-blind, controlled trial 2023 · myo-inositol group · Overweight pregnant women at 12–14 weeks of gestation | 400 mcg | 2 g | 10 weeks | — |
| Myo-inositol Supplementation for Prevention of Gestational Diabetes in Obese Pregnant Women: A Randomized Controlled Trial 2015 · myo-inositol · Pregnant obese women (prepregnancy BMI 30 or greater) | 400 mcg | 4 g | — | 110 |
| Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial 2016 · myo-inositol group · Pregnant overweight, non-obese women with pre-pregnancy BMI ≥25 and <30 kg/m² | 400 mcg | 4 g | — | 110 |
| Effect of dietary myo-inositol supplementation on the insulin resistance and the prevention of gestational diabetes mellitus: an open-label, randomized controlled trial 2024 · MI group · Pregnant women at 11–13+6 weeks of gestation | 400 mcg | 4 g | — | 100 |
| Insulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women 2010 · MYO plus folic acid, with r-FSH added if no pregnancy occurred · Women with polycystic ovary syndrome, menstrual irregularities, chronic anovulation, and female infertility; ages not reported | 400 mcg | 4 g | — | 60 |
| myo-Inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study 2013 · myo-inositol group · Pregnant women recruited at 12–13 weeks’ gestation with a first-degree relative with type 2 diabetes, prepregnancy BMI <30 kg/m², and no pregestational diabetes or PCOS | 400 mcg | 4 g | — | — |
| The effect of myo-inositol, vitamin D3 and melatonin on the oocyte quality and pregnancy in in vitro fertilization: a randomized prospective controlled trial 2020 · Study group · Women undergoing ICSI | 600 mcg | 3.2 g | 26 weeks | 50 |
| Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS 2007 · myo-inositol plus folic acid · Women with oligomenorrhea and polycystic ovaries | 400 mcg | 4 g | 14 weeks | 45 |
| [Diet, metformin and inositol in overweight and obese women with polycystic ovary syndrome: effects on body composition] 2012 · diet, metformin and MYO (D+M+I) · Overweight or obese women with polycystic ovary syndrome; age not reported | 400 mcg | 4 g | 90 days | 9 |
| Myoinositol/folic acid combination for the treatment of erectile dysfunction in type 2 diabetes men: a double-blind, randomized, placebo-controlled study 2006 · myoinositol/folic acid combination · men with type 2 diabetes and erectile dysfunction | 400 mcg | 4 g | — | — |
| Effects of myo-inositol supplementation on oocyte's quality in PCOS patients: a double blind trial 2011 · Group A · Women with polycystic ovary syndrome undergoing IVF | 400 mcg | 4 g | 90 days | — |
| The myo-inositol effect on the oocyte quality and fertilization rate among women with polycystic ovary syndrome undergoing assisted reproductive technology cycles: a randomized clinical trial 2019 · study group · infertile women with PCOS undergoing assisted reproductive technology cycles; age not reported | 400 mg | 4 g | 30 days | — |
| The impact of myo-inositol supplementation on sleep quality in pregnant women: a randomized, double-blind, placebo-controlled study 2022 · myo-inositol supplementation · Pregnant women with low-risk singleton pregnancies, at least 14 weeks’ gestation | 200 mcg | 2 g | 10 weeks | — |
| Improvement in biochemical manifestations of the serum and follicular fluid and ICSI outcomes in PCOS patients with myo-inositol administration: prospective randomized research 2025 · MI group · Infertile women with PCOS undergoing ovulation induction for ICSI; age not reported | 2 mg | 4 g | 6 weeks | — |
| A pilot study of D-chiro-inositol plus folic acid in overweight patients with type 1 diabetes 2017 · treated group · Overweight or obese patients with type 1 diabetes receiving intensive insulin therapy | 400 mcg | 1 g | 24 weeks | — |
| Effect of inositol stereoisomers at different dosages in gestational diabetes: an open-label, parallel, randomized controlled trial 2018 · DCI treatment · Pregnant women with gestational diabetes mellitus | 400 mcg | 500 mg | 8 weeks | 20 |
| Myo-inositol nutritional supplement for prevention of gestational diabetes (EMmY): a randomised, placebo-controlled, double-blind pilot trial with nested qualitative study 2022 · intervention (myo-inositol) · Pregnant women aged at least 16 years with a singleton pregnancy at 12+0 to 15+6 weeks’ gestation and high risk of gestational diabetes | 400 mcg | 4 g | — | 99 |
| Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS 2014 · D-chiro-inositol group · Women with PCOS and menstrual irregularities | 400 mcg | 1 g | 26 weeks | 25 |
| Maternal B-vitamin and vitamin D status before, during, and after pregnancy and the influence of supplementation preconception and during pregnancy: Prespecified secondary analysis of the NiPPeR double-blind randomized controlled trial 2023 · intervention · Women planning pregnancy; generally healthy, recruited before conception | 400 mcg | 4 g | — | 870 |
| Myoinositol plus α-lactalbumin supplementation, insulin resistance and birth outcomes in women with gestational diabetes mellitus: a randomized, controlled study 2021 · Treated group · Women aged 18–44 with gestational diabetes mellitus and a singleton pregnancy | 400 mcg | 4 g | 60 days | 60 |
| Effect of myo-inositol supplementation on ICSI outcomes among poor ovarian responder patients: A randomized controlled trial 2020 · Group A · Poor responder patients undergoing ICSI; age and sex details not reported | 400 mcg | 4 g | — | 56 |
| Inositol for the prevention of neural tube defects: a pilot randomised controlled trial 2016 · inositol+FA group · Women aged 18–40 planning pregnancy, with a history of a previous neural tube defect-affected pregnancy | 5 mg | 1 g | — | 25 |
| The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes 2011 · study group · Women with gestational diabetes treated with diet | 400 mcg | 4 g | 8 weeks | 24 |
| Effect of inositol stereoisomers at different dosages in gestational diabetes: an open-label, parallel, randomized controlled trial 2018 · MI treatment · Pregnant women with gestational diabetes mellitus | 400 mcg | 4 g | 8 weeks | 20 |
| Effect of inositol stereoisomers at different dosages in gestational diabetes: an open-label, parallel, randomized controlled trial 2018 · MI plus DCI treatment · Pregnant women with gestational diabetes mellitus | 400 mcg | 1.13 g | 8 weeks | 20 |
| Effect of Myo-Inositol Treatment on Serum Asprosin Levels of Pregnant Women: A Prospective Randomized Controlled Pilot Study 2025 · Group 1 · Pregnant women aged 18–40 without the stated exclusion conditions | 400 mcg | 4 g | 21 weeks | 20 |
| Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome 2008 · Group A · Overweight patients with polycystic ovary syndrome; age and sex details not stated | 200 mcg | 2 g | 12 weeks | 10 |
| Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study 2013 · Group A · Overweight patients with polycystic ovary syndrome; age and sex not specified | 200 mg | 2 g | 12 weeks | 10 |
| Effect of myo-inositol and melatonin versus myo-inositol, in a randomized controlled trial, for improving in vitro fertilization of patients with polycystic ovarian syndrome 2016 · Group A · Women of reproductive age with polycystic ovarian syndrome undergoing IVF | 400 mcg | 4 g | — | — |
| Effect of myo-inositol and melatonin versus myo-inositol, in a randomized controlled trial, for improving in vitro fertilization of patients with polycystic ovarian syndrome 2016 · Group B · Women of reproductive age with polycystic ovarian syndrome undergoing IVF | 400 mcg | 4 g | — | — |
| The ameliorative effect of myo-inositol on apoptosis-related genes expression in cumulus cells of women with polycystic ovary syndrome undergoing ICSI and its relationship with the quality of oocyte and embryo 2025 · MYO group · Infertile women with PCOS undergoing ICSI; age range and sex beyond women not reported | 2 mg | 4 g | 6 weeks | — |
| Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS 2014 · Myo-inositol group · Women with PCOS and menstrual irregularities | 400 mcg | 4 g | 26 weeks | 25 |
| The effectiveness of inositol and metformin on infertile polycystic ovary syndrome women with resistant to letrozole 2019 · Group III · Infertile women with polycystic ovary syndrome who did not ovulate after letrozole treatment | 400 mcg | 4 g | 90 days | — |
